|
US4369184A
(en)
|
1980-01-24 |
1983-01-18 |
Janssen Pharmaceutica N.V. |
1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
|
|
JPS56110674A
(en)
|
1980-01-24 |
1981-09-01 |
Janssen Pharmaceutica Nv |
Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative
|
|
US5852029A
(en)
|
1990-04-10 |
1998-12-22 |
Israel Institute For Biological Research |
Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
|
|
GB9300194D0
(en)
|
1993-01-06 |
1993-03-03 |
Wyeth John & Brother Ltd |
Piperazine derivatives
|
|
US5446051A
(en)
|
1994-05-31 |
1995-08-29 |
Eli Lilly And Company |
Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
|
|
JP2002515008A
(ja)
|
1994-10-27 |
2002-05-21 |
メルク エンド カンパニー インコーポレーテッド |
ムスカリン・アンタゴニスト
|
|
IL117149A0
(en)
|
1995-02-23 |
1996-06-18 |
Schering Corp |
Muscarinic antagonists
|
|
US5889006A
(en)
|
1995-02-23 |
1999-03-30 |
Schering Corporation |
Muscarinic antagonists
|
|
WO1997016187A1
(en)
|
1995-10-31 |
1997-05-09 |
Merck & Co., Inc. |
Muscarine antagonists
|
|
US5854245A
(en)
|
1996-06-28 |
1998-12-29 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
|
AU3632297A
(en)
|
1996-08-26 |
1998-03-19 |
Pfizer Inc. |
Spirocyclic dopamine receptor subtype ligands
|
|
WO1998057641A1
(en)
|
1997-06-18 |
1998-12-23 |
Merck & Co., Inc. |
ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
|
|
GB9715892D0
(en)
|
1997-07-29 |
1997-10-01 |
Zeneca Ltd |
Heterocyclic compounds
|
|
AU2206699A
(en)
|
1997-12-23 |
1999-07-12 |
Alcon Laboratories, Inc. |
Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
|
|
AU2307999A
(en)
|
1997-12-23 |
1999-07-12 |
Alcon Laboratories, Inc. |
Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
|
|
AU2307899A
(en)
|
1997-12-23 |
1999-07-12 |
Alcon Laboratories, Inc. |
Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
|
|
WO1999032479A1
(en)
|
1997-12-23 |
1999-07-01 |
Alcon Laboratories, Inc. |
Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists
|
|
CZ286152B6
(cs)
|
1998-03-13 |
2000-01-12 |
Miroslav Ing. Csc. Vlček |
Transparentní a semitransparentní difrakční prvky
|
|
US6387930B1
(en)
|
1999-05-04 |
2002-05-14 |
Schering Corporation |
Piperidine derivatives useful as CCR5 antagonists
|
|
CN1349408A
(zh)
|
1999-05-04 |
2002-05-15 |
先灵公司 |
聚乙二醇化干扰素α－CCR5拮抗剂联合HIV疗法
|
|
HK1039330B
(en)
|
1999-05-04 |
2005-12-09 |
Schering Corporation |
Piperidine derivatives useful as ccr5 antagonists
|
|
US6420364B1
(en)
|
1999-09-13 |
2002-07-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compound useful as reversible inhibitors of cysteine proteases
|
|
YU17402A
(sh)
|
1999-09-13 |
2004-11-25 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Nova spiroheterociklična jedinjenja upotrebljiva kao reverzibilni inhibitori cisteinskih proteaza
|
|
US6921763B2
(en)
|
1999-09-17 |
2005-07-26 |
Abbott Laboratories |
Pyrazolopyrimidines as therapeutic agents
|
|
ATE275141T1
(de)
|
1999-10-13 |
2004-09-15 |
Banyu Pharma Co Ltd |
Substituierte imidazolin-derivate
|
|
AU2001297648A1
(en)
|
2000-11-28 |
2002-08-28 |
Eli Lilly And Company |
Substituted carboxamides as inhibitors of factor xa
|
|
JPWO2002085890A1
(ja)
|
2001-04-20 |
2004-08-12 |
萬有製薬株式会社 |
ベンズイミダゾロン誘導体
|
|
BR0210391A
(pt)
|
2001-06-12 |
2004-06-15 |
Elan Pharm Inc |
Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
|
|
WO2004089942A2
(en)
|
2001-10-02 |
2004-10-21 |
Acadia Pharmaceuticals Inc. |
Benzimidazolidinone derivatives as muscarinic agents
|
|
GB0128378D0
(en)
|
2001-11-27 |
2002-01-16 |
Smithkline Beecham Plc |
Novel Compounds
|
|
US7550459B2
(en)
|
2001-12-28 |
2009-06-23 |
Acadia Pharmaceuticals, Inc. |
Tetrahydroquinoline analogues as muscarinic agonists
|
|
NZ533566A
(en)
|
2001-12-28 |
2007-03-30 |
Acadia Pharm Inc |
Tetrahydroquinoline analogues as muscarinic agonists
|
|
US20040171614A1
(en)
|
2002-02-06 |
2004-09-02 |
Schering-Plough Corporation |
Novel gamma secretase inhibitors
|
|
US7256186B2
(en)
|
2002-02-06 |
2007-08-14 |
Schering Corporation |
Gamma secretase inhibitors
|
|
AU2003221178B2
(en)
|
2002-03-28 |
2006-06-15 |
Tanabe Seiyaku Co., Ltd. |
Benzofuran derivative
|
|
AU2003242252A1
(en)
|
2002-06-07 |
2003-12-22 |
Kyowa Hakko Kogyo Co., Ltd. |
Bicyclic pyrimidine derivatives
|
|
HK1079787A1
(zh)
|
2002-07-31 |
2006-04-13 |
Ranbaxy Laboratories Limited |
用作毒蕈碱受体拮抗剂的3，6-二取代的氮杂双环[3．1．0]己烷衍生物
|
|
MXPA05003344A
(es)
|
2002-09-30 |
2005-11-23 |
Neurosearch As |
Derivados novedosos de 1,4-diazabicicloalcano, su preparacion y uso.
|
|
KR100772297B1
(ko)
|
2002-11-22 |
2007-11-02 |
니뽄 다바코 산교 가부시키가이샤 |
융합 비시클릭 질소-함유 헤테로사이클
|
|
MXPA05005660A
(es)
|
2002-11-27 |
2005-10-18 |
Incyte Corp |
Derivados de 3-aminopirrolidina como moduladores de receptores de quimocina.
|
|
WO2004069828A1
(ja)
|
2003-02-04 |
2004-08-19 |
Mitsubishi Pharma Corporation |
ピペリジン化合物およびその医薬用途
|
|
CA2529686C
(en)
|
2003-07-17 |
2010-06-15 |
Astellas Pharma Inc. |
2-acylaminothiazole derivative or salt thereof
|
|
EP1679069A4
(en)
|
2003-10-21 |
2009-05-13 |
Dainippon Sumitomo Pharma Co |
NEW PIPERIDINE DERIVATIVE
|
|
EP1725235B1
(en)
|
2004-02-05 |
2009-04-15 |
Schering Corporation |
Piperidine derivatives useful as ccr3 antagonists
|
|
KR100863854B1
(ko)
|
2004-02-10 |
2008-10-15 |
에프. 호프만-라 로슈 아게 |
케모카인 ｃｃｒ5 수용체 조절제
|
|
US7488745B2
(en)
|
2004-07-16 |
2009-02-10 |
Schering Corporation |
Compounds for the treatment of inflammatory disorders
|
|
US7504424B2
(en)
|
2004-07-16 |
2009-03-17 |
Schering Corporation |
Compounds for the treatment of inflammatory disorders
|
|
US7786141B2
(en)
|
2004-08-19 |
2010-08-31 |
Vertex Pharmaceuticals Incorporated |
Dihydrospiroindene modulators of muscarinic receptors
|
|
US7880007B2
(en)
|
2004-11-29 |
2011-02-01 |
Vertex Pharmaceuticals Incorporated |
Bicyclic substituted phenyl piperidine modulators of muscarinic receptors
|
|
JP4774995B2
(ja)
|
2005-01-12 |
2011-09-21 |
アステラス製薬株式会社 |
アシルアミノチアゾール誘導体を有効成分とする医薬組成物
|
|
WO2006105035A2
(en)
|
2005-03-28 |
2006-10-05 |
Vertex Pharmaceuticals Incorporated |
Muscarinic modulators
|
|
WO2006137485A1
(ja)
|
2005-06-24 |
2006-12-28 |
Toyama Chemical Co., Ltd. |
新規な含窒素複素環化合物およびその塩
|
|
US7858635B2
(en)
|
2005-12-22 |
2010-12-28 |
Vertex Pharmaceuticals Incorporated |
Spiro compounds as modulators of muscarinic receptors
|
|
TW200801008A
(en)
|
2005-12-29 |
2008-01-01 |
Abbott Lab |
Protein kinase inhibitors
|
|
NZ570497A
(en)
|
2006-02-22 |
2011-09-30 |
Vertex Pharma |
Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
|
|
CN101426499A
(zh)
|
2006-02-22 |
2009-05-06 |
弗特克斯药品有限公司 |
毒蕈碱受体调节剂
|
|
EP2051712A2
(en)
|
2006-08-15 |
2009-04-29 |
Vertex Pharmceuticals Incorporated |
Modulators of muscarinic receptors
|
|
US20130012485A1
(en)
|
2006-12-22 |
2013-01-10 |
Baeschlin Daniel Kaspar |
Organic compounds
|
|
WO2008117229A1
(en)
*
|
2007-03-23 |
2008-10-02 |
Ranbaxy Laboratories Limited |
Muscarinic receptor antagonists
|
|
US8119661B2
(en)
|
2007-09-11 |
2012-02-21 |
Astrazeneca Ab |
Piperidine derivatives and their use as muscarinic receptor modulators
|
|
AU2009228931B2
(en)
|
2008-03-27 |
2013-05-23 |
Janssen Pharmaceutica Nv |
Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
|
|
JP2012506883A
(ja)
|
2008-10-29 |
2012-03-22 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
置換されたスピロアミン
|
|
HUE025547T2
(en)
|
2008-12-19 |
2016-02-29 |
Boehringer Ingelheim Int |
Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
|
|
CN102459227B
(zh)
|
2009-04-17 |
2014-08-20 |
詹森药业有限公司 |
Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂
|
|
FR2945531A1
(fr)
|
2009-05-12 |
2010-11-19 |
Sanofi Aventis |
Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
|
|
US20130197027A1
(en)
|
2010-03-10 |
2013-08-01 |
Craig Lindsley |
Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same
|
|
JP2013525370A
(ja)
|
2010-04-22 |
2013-06-20 |
ヤンセン ファーマシューティカ エヌ．ベー． |
ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
|
|
US8921394B2
(en)
|
2010-04-27 |
2014-12-30 |
Merck Sharp & Dohme Corp. |
Prolylcarboxypeptidase inhibitors
|
|
US9365539B2
(en)
|
2010-05-11 |
2016-06-14 |
Merck Sharp & Dohme Corp. |
Prolylcarboxypeptidase inhibitors
|
|
WO2011150183A1
(en)
|
2010-05-28 |
2011-12-01 |
Ge Healthcare Limited |
Radiolabeled compounds and methods thereof
|
|
US20130184257A1
(en)
|
2010-09-17 |
2013-07-18 |
Thomas Daniel Aicher |
Piperidinyl-substituted lactams as gpr119 modulators
|
|
WO2012125661A1
(en)
|
2011-03-17 |
2012-09-20 |
Merck Sharp & Dohme Corp. |
Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists
|
|
JP2013010719A
(ja)
|
2011-06-30 |
2013-01-17 |
Dainippon Sumitomo Pharma Co Ltd |
ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
|
|
AU2012338581B2
(en)
|
2011-11-18 |
2016-12-08 |
Nxera Pharma Uk Limited |
Muscarinic M1 receptor agonists
|
|
BR112015006029B1
(pt)
|
2012-09-18 |
2022-01-25 |
Heptares Therapeutics Limited |
Compostos aza bicíclicos como agonistas de receptor m1 muscarínicos, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou distúrbio psicótico ou para tratar ou reduzir a gravidade de dores agudas, crônicas, neuropáticas ou inflamatórias
|
|
WO2014122474A1
(en)
|
2013-02-07 |
2014-08-14 |
Takeda Pharmaceutical Company Limited |
Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
|
|
KR102352388B1
(ko)
|
2014-02-06 |
2022-01-17 |
헵테얼즈 테라퓨틱스 리미티드 |
무스카린성 m1 수용체 및/또는 m4 수용체 작용제로서 바이사이클릭 아자 화합물
|
|
GB201404922D0
(en)
|
2014-03-19 |
2014-04-30 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
EP3265459B1
(en)
|
2015-02-13 |
2019-05-15 |
Suven Life Sciences Limited |
Amide compounds as 5-ht4 receptor agonists
|
|
GB201504675D0
(en)
|
2015-03-19 |
2015-05-06 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
GB201513740D0
(en)
|
2015-08-03 |
2015-09-16 |
Heptares Therapeutics Ltd |
Muscarinic agonist
|
|
GB201513743D0
(en)
|
2015-08-03 |
2015-09-16 |
Heptares Therapeutics Ltd |
Muscarinic agonists
|
|
GB201513742D0
(en)
|
2015-08-03 |
2015-09-16 |
Heptares Therapeutics Ltd |
Muscarinic agonists
|
|
GB201519352D0
(en)
|
2015-11-02 |
2015-12-16 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
GB201617454D0
(en)
|
2016-10-14 |
2016-11-30 |
Heptares Therapeutics Limited |
Pharmaceutical compounds
|
|
US10259787B2
(en)
|
2016-10-14 |
2019-04-16 |
Heptares Therapeutics Limited |
Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
|
|
GB201709652D0
(en)
*
|
2017-06-16 |
2017-08-02 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
US10501483B2
(en)
|
2017-10-24 |
2019-12-10 |
Allergan, Inc. |
Enamines and diastereo-selective reduction of enamines
|
|
GB201810245D0
(en)
|
2018-06-22 |
2018-08-08 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
GB201810239D0
(en)
|
2018-06-22 |
2018-08-08 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
GB201819960D0
(en)
|
2018-12-07 |
2019-01-23 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
GB201819961D0
(en)
|
2018-12-07 |
2019-01-23 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
GB202020191D0
(en)
|
2020-12-18 |
2021-02-03 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
GB202103211D0
(en)
|
2021-03-08 |
2021-04-21 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds for use in therapy
|